A new generation of hereditary angioedema treatments: Remarkable advances clash with disturbing economic reality

Annals of Allergy, Asthma and Immunology

Volumn 106, Issue 4, 2011, Pages 264-266

  Tilles, Stephen A ^a   Borish, Larry ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; COMPLEMENT COMPONENT C1S INHIBITOR; DANAZOL; ECALLANTIDE; KALBITOR; TRANEXAMIC ACID; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ALOPECIA; ANGIONEUROTIC EDEMA; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; EDITORIAL; HIRSUTISM; HUMAN; LIVER TOXICITY; METRORRHAGIA; MORBIDITY; MORTALITY; MYALGIA; PRIORITY JOURNAL; PROTEIN SYNTHESIS; SIDE EFFECT; TREATMENT RESPONSE; WEIGHT GAIN;

ANGIOEDEMAS, HEREDITARY; COMPLEMENT C1 INACTIVATOR PROTEINS; HUMANS;

EID: 79953295551     PISSN: 10811206     EISSN: 15344436     Source Type: Journal    
DOI: 10.1016/j.anai.2011.01.025     Document Type: Editorial

References (5)

1. Hosea SW, Santaella ML, Brown EJ, Berger M, Katusha K, Frank MM. Long term therapy of hereditary angioedema with danazol. Ann Intern Med. 1980;93:809-812. (Pubitemid 11197781)
2. US Department of Health and Human Services. Food and Drug Administration. Developing Drugs and Products for rare Diseases and Conditions. http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/ default.htm.
3. Zuraw BL, Busse PJ, White M, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med. 2010;363:513-522.
4. Riedl MA, Gower RG, Chrvala CA. Current management of hereditary angioedema: results from a large survey of US physicians. Ann Allergy. 2011;106:314-320.
5. Cocchio C, Marzella N. Cinryze, a human plasma derived C1 esterase inhibitor for prophylaxis of hereditary angioedema. P T. 2009;34:293-328.